Serimmune

Serimmune Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $1.41M
Latest Deal Amount
  • Investors
  • 4

Serimmune General Information

Description

Developer of immune mapping platform intended to map circulating antibodies to their diverse antigens. The company's ML-based platform applies bacterial display peptide libraries, next-generation sequencing and custom bioinformatics to map the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases and cancers, enabling medical practitioners to combat infectious and autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 150 Castilian Drive
  • Suite 100
  • Goleta, CA 93117
  • United States

Serimmune Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Serimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 30-May-2019 $1.41M 000.00 Completed Startup
4. Early Stage VC 20-Jun-2017 000 000.00 Completed Startup
3. Early Stage VC 30-Dec-2016 00.00 00.000 0000 Completed Startup
2. Grant 01-Jan-2016 $225K $850K Completed Startup
1. Early Stage VC (Series A) 13-Jan-2015 $850K $850K 00.000 Completed Startup

Serimmune Cap Table

To view Serimmune‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 000
Series A 000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000

Serimmune Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Arisan Therapeutics Accelerator/Incubator Backed San Diego, CA 000000000000
0000 000000000000 Venture Capital-Backed Schlieren, Switzerland 00.000 00000000000 00.000
000000000 Venture Capital-Backed Vancouver, Canada 000 00000 00000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00

Serimmune Executive Team (2)

Name Title Board Seat Contact Info
Patrick Daugherty Ph.D Founder, Chief Executive Officer, Chief Science Officer & Board Member
John Shon MD Chief Technology Officer

Serimmune Board Members (5)

Name Representing Role Since
Bill Welch Serimmune Board Member 000 0000
Kristin Loomis Serimmune Board Member 000 0000
Nicholas Naclerio Ph.D Illumina Ventures Board Member 000 0000
Patrick Daugherty Ph.D Serimmune Founder, Chief Executive Officer, Chief Science Officer & Board Member 000 0000
Thomas Willis Ph.D Illumina Ventures Board Member 000 0000

Serimmune Investors (4)

To view Serimmune‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Illumina Ventures Venture Capital Minority 000 0000 000000 0
LabCorp Ventures Corporate Venture Capital Minority 000 0000 000000 0
Merck Corporation Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Ready to get started?

Request a free trial